Drug Type Hematopoietic stem cell therapy |
Synonyms Ex vivo expanded universal donor cellular therapies Nohla Therapeutics, Ex vivoexpanded cord blood progenitor cells, Haematopoetic progenitor cell therapy Nohla Therapeutics + [3] |
Target- |
Mechanism Cell replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationFast Track (US), Orphan Drug (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Leukopenia | Phase 3 | US | 21 Jan 2018 | |
Hematologic Neoplasms | Phase 3 | US | 22 Jul 2010 | |
acute leukemia | Phase 2 | US | 10 May 2022 | |
Acute Lymphoblastic Leukemia | Phase 2 | US | 10 May 2022 | |
Acute Lymphoblastic Leukemia | Phase 2 | US | 10 May 2022 | |
Acute Lymphoblastic Leukemia | Phase 2 | US | 10 May 2022 | |
Chronic phase chronic myeloid leukemia | Phase 2 | US | 10 May 2022 | |
Chronic phase chronic myeloid leukemia | Phase 2 | US | 10 May 2022 | |
Chronic phase chronic myeloid leukemia | Phase 2 | US | 10 May 2022 | |
Acute Myeloid Leukemia | Phase 2 | US | Deverra Therapeutics, Inc.Startup | - |
Phase 2 | 163 | Umbilical Cord Blood Transplantation+Cyclosporine+Fludarabine Phosphate+Cyclophosphamide+mycophenolate mofetil+Thiotepa (Arm I (Standard of Care)) | wwsnlbdcus(tuvaxhejxy) = wbigaupgup nnhazewxxl (jqnioxlaub, bujtvrynkn - tzlqvrpvlo) View more | - | 06 Jul 2021 | ||
Umbilical Cord Blood Transplantation+Ex Vivo-Expanded Cord Blood Progenitor Cell Infusion+Cyclosporine+Fludarabine Phosphate+Cyclophosphamide+mycophenolate mofetil+Thiotepa (Arm II (Experimental)) | wwsnlbdcus(tuvaxhejxy) = zuickexzpv nnhazewxxl (jqnioxlaub, cezmwbzvvt - inqpmhebpy) View more | ||||||
Phase 2 | 16 | acgxkluuru(jwopcbyupa) = sdtyrdaall xprblcrubo (ofrbkdgrbc ) View more | Positive | 15 Jun 2018 | |||
Standard of Care | acgxkluuru(jwopcbyupa) = znhzpypexu xprblcrubo (ofrbkdgrbc ) View more |